Harmony Biosciences
Presence
Harmony Biosciences is one of the...
Harmony Biosciences is a company listed under the stock ticker HRMY (US).
Acquisition, funding and merger involving Harmony Biosciences.
- Harmony Biosciences has announced the acquisition of Zynerba Pharmaceuticals (posted on August 15 2023).
Executives
View the org chart displaying its 38 main executives
Most searched biographies at Harmony Biosciences
- Jeffrey Dayno, President and Chief Executive Officer
- Jeffrey Aronin, Non-Executive Chairman
- Mark Graf, Director
Popular executive movements at Harmony Biosciences
- Peter Anastasiou has joined the company as Director (posted on November 9 2023).
- Sandip Kapadia, who was Chief Financial Officer, is promoted to Chief Financial Officer and Chief Administrative Officer (posted on October 6 2023).
Create your alert
to follow the executive moves at Harmony Biosciences.
Biotechnology
Harmony Biosciences has 2,286 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Harmony Biosciences
- HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME | Harmony Biosciences
- HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST | Harmony Biosciences
- HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 | Harmony Biosciences
- HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE | Harmony Biosciences
- HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES | Harmony Biosciences
- Harmony Biosciences Certified as a Great Place to Work® for Sixth Consecutive Year, Underscoring Ongoing Commitment to Employee Satisfaction and Growth | Harmony Biosciences
- HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME | Harmony Biosciences
- HARMONY BIOSCIENCES EXPANDS COMMITMENT TO THE RARE NEUROLOGICAL DISEASE COMMUNITY WITH CALL FOR PROGRESS AT THE HEART AND PATIENTS AT THE HEART APPLICATIONS | Harmony Biosciences
- U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY | Harmony Biosciences
- Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Harmony Biosciences
- View more press releases Close
Social media about Harmony Biosciences
- Harmony Biosciences on Wikipedia, Google News & Yahoo Finance
- Harmony Biosciences on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Jeffrey Dayno 
Call Harmony Biosciences at +1 484...
